Where does Innate Tumor Immunity, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Innate Tumor Immunity, Inc. ranks #14,060 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Innate Tumor Immunity, Inc. hold?

Innate Tumor Immunity, Inc. holds 21 US utility patents granted between 2020 and 2025, spanning 6 technology areas.

What is Innate Tumor Immunity, Inc.'s Innovation Score?

Innate Tumor Immunity, Inc. has an Innovation Score of 36.3 out of 100 (top 47% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Innate Tumor Immunity, Inc. focus on?

Innate Tumor Immunity, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 19 patents, ranking #1,031 of 6,058 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Innate Tumor Immunity, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Innate Tumor Immunity, Inc..

What does claim depth mean for Innate Tumor Immunity, Inc.'s patents?

Innate Tumor Immunity, Inc.'s patents average 14.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Innate Tumor Immunity, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Innate Tumor Immunity, Inc.

USPTO PatentsView assignee record - 21 granted patents across 6 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Innate ranks #14,060 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 6 technology areas.

#14,060
of 49,997 US assignees by volume: Top 47%
by Innovation Score (36.3/100): 14.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R14060 · US Corporation #14,060 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 21 grants
MID-PACK #14,060/49,997
PHOTO-FINISH Incipio
CPC-NARROW A61P · 6 areas
INNOV-THIN 36.3/100
CLAIMS-RICH 14.0 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Incipio Technologies, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Innate’s 36.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.7 pts (29%) Velocity 8.6 pts (24%) Breadth 8.7 pts (24%) Claim depth 8.4 pts (23%)

Qualcomm Incorporated · highest

85
Innate Tumor Immunity · this assignee

36
3D Lighting… · lowest

7

What this shows Innate's Innovation Score is 36.3/100 (top 47% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Innate?

Each dot is one of Innate’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Innate’s own 14.0 claims/patent is ABOVE the 13.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Innate vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Innate's grants concentrate

Innate Tumor Immunity, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 90.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (5 grants) versus a trough of 2 in 2021. By volume, Innate sits between Incipio Technologies, Inc. and Intelligent Mechatronic Systems Inc..

Innate's three-year grant acceleration

Innate Tumor Immunity, Inc. shows 9 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Incipio

21
Indian Institute…

21
Infinium Technolo…

21
Inline Plastics

21
Innocare Optoelec…

21
Innovaprep

21
Integran

21
Intelligent Mecha…

21
Innate Tumor Immu… ◀

21

What this shows Innate holds 21 patents at rank #14,072, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Innate

By rank, the assignees closest to #14,072 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Innate's primary technology class.

Innate's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 47% higher than 53% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Innate Tumor Immunity, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	5	23.8%
2021	2	9.5%
2022	2	9.5%
2023	3	14.3%
2024	4	19.0%
2025partial year	5	23.8%

Which technologies does Innate Tumor Immunity, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 19

C07D - Heterocyclic Compounds 17

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 16

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 4

C07K - Peptides 3

Y02A - Technologies FOR Adaptation TO Climate Change 2

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Innate Tumor Immunity, Inc.'s patent record in context - here's where to go next.

Innate Tumor Immunity, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 90.5% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #14,060 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Innate Tumor Immunity, Inc. against Incipio Technologies, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.